{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"111.600","floor":"94.400"},"ipodate":{"start":"2018-07-30 00:00:00","end":"2018-08-02 00:00:00"},"minimumcapital":"11272.46","subscribed":"1.73","marketcap":"828.54億","H_marketcap":"--","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/06160/LTN20180730006_C.pdf","ipopricing":"108.000","resultdate":"2018-08-07 00:00:00","enddate":"2018-08-02 00:00:00","listeddate":"2018-08-08 00:00:00","issuenumber":"6560.00萬","issuenumberhK":"590.40萬","issuenumberother":"5969.60萬","grayprice":"105.70","sponsors":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司","raisemoney":"682800.00萬","use":"1、75%（或4,857.4百萬港元）用于zanubrutinib、tislelizumab及pamiparib：\n2、15%或（或971.5百萬港元）將用于透過內部研究及外部授權及業務發展合作，為我們在癌癥及其他潛在治療領域的產品組合持續擴充提供資金；\n3、10%或（或647.6百萬港元）用作營運資金、拓展內部能力及一般企業目的。","shares":100,"leadagent":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,瑞士信貸(香港)有限公司,中信里昂證券有限公司,中國國際金融香港證券有限公司,德意志銀行香港分行,瑞士銀行香港分行,華興證券(香港)有限公司","bookrunners":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,瑞士信貸(香港)有限公司,中信里昂證券有限公司,中國國際金融香港證券有限公司,德意志銀行香港分行,瑞士銀行香港分行","coordinator":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,瑞士信貸(香港)有限公司,中信里昂證券有限公司","firstDayOpen":"108.00","IsEiio":0,"Interestdays":5,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E06160","name":"百濟神州－Ｂ","fullname":"BeiGene, Ltd."},"institutioninfo":{"principaloffice":"中國北京市昌平區中關村生命科學園科學園路30號","registrars":"香港中央證券登記有限公司","registrarstel":"(852)2862 8628","chairman":"歐雷強","secretary":"Chau Hing Ling","telephone":"","substantialshareholders":"Baker Bros. Advisors LP(21.09%),Gaoling Fund, L.P.(7.69%)","principalactivities":"公司是一家商業階段的生物技術公司，專注于開發及商業化用于治療癌癥的創新型分子靶向及腫瘤免疫治療藥物。","website":"http://www.beigene.com"},"managerinfo":[{"managername":"歐雷強","post":"執行董事、主席兼行政總裁","rankno":1},{"managername":"王曉東","post":"非執行董事","rankno":2},{"managername":"陳永正","post":"獨立非執行董事","rankno":3}],"investorinfo":[{"institutionname":"GIC Private Limited","shareholding":"7,267,600.0","percentage":11.08,"ReleaseDate":"2019-02-08 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Baker Brothers Life Sciences, L.P.","shareholding":"5,814,100.0","percentage":8.86,"ReleaseDate":"2019-02-08 00:00:00","relatedparty":"Baker Bros.Advisors LP","subsidiary":["Baker Brothers Life Sciences, L.P."],"InverstorType":"基金"},{"institutionname":"Hillhouse Funds","shareholding":"5,424,000.0","percentage":8.27,"ReleaseDate":"2019-02-08 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"Ally Bridge LB Healthcare Master Fund Limited","shareholding":"1,816,900.0","percentage":2.77,"ReleaseDate":"2019-02-08 00:00:00","relatedparty":"Ally Bridge LB Management Limited","subsidiary":["Ally Bridge LB Healthcare Master Fund Limited"],"InverstorType":"基金"}],"TotalShareholdingPercentage":30.98},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":510}